For instance, Jin et al. reported a lower expression of ULK1 in human AML cell lines [251], while Hwang et al. indicated a significantly higher level of ULK1 in FLT3-ITD-mutated AML cells compared to FLT3-wild-type AML cells, which ultimately suggested that inhibiting ULK1 in FLT3-ITD AML cells might be a promising therapeutic approach against FLT3-ITD-mutated AML [252]. This evidence concerns the gene ULK1 and acute myeloid leukemia.